Caribou Biosciences (CRBU) appointed Sri Ryali as CFO, effective immediately. Most recently, Ryali served as CFO of Codexis, a publicly traded enzyme engineering company. Previously, he served as CFO of Eiger BioPharmaceuticals, then a publicly traded, commercial-stage company. Previously at Aimmune Therapeutics, Ryali held roles of increasing responsibility, most recently as VP of Finance. Earlier in his career, he worked at Onyx Pharmaceuticals and Amgen in finance-related positions of increasing responsibility.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBU:
- Shareholders of Caribou Biosciences, Inc. Should Contact Levi & Korsinsky LLP Before February 24, 2025 to Discuss Your Rights – CRBU
- Caribou (CRBU) Develops Transformative Cell Therapies and Captures Investors’ Attention
- Caribou Biosciences price target lowered to $6 from $30 at Citi
- Caribou Biosciences Reports Q3 2024 Financial Results
- Caribou Biosciences reports Q3 EPS (38c), consensus (45c)